Professor Andreas Hochhaus

Andreas Hochhaus, is Director of the Department of Hematology and Medical Oncology, Coordinator of the University Tumor Center and co-Director of the Comprehensive Cancer Center Central Germany at Jena University Hospital in Germany. 

He is Full Professor for Internal Medicine / Hematology and Oncology at the Friedrich-Schiller-University in Jena. 

He studied medicine in Erfurt, completed his clinical training at the university of Erfurt and the University of Mannheim, and his doctoral thesis in internal medicine and hematology at the University Erfurt.

Professor Andreas Hochhaus has played a major role in developing imatinib and next-generation TKIs, participating in many pivotal CML trials and advancing combination therapies. He has participated in studies with the German CML Study Group for over 30 years, and is lead investigator of the TIGER trial and co-ordinator for the EUTOS for CML initiative. His recent work focuses on asciminib and translational research in CML and other cancers, molecular monitoring, and the role of BCR::ABL1 independent mutations.

He was lead author of the 2020 ELN CML recommendations and as Co-chair of the German CML Alliance, he actively promotes clinical trial access and patient engagement.

Andreas Hochhaus has published 710 peer-reviewed papers and is Co-Editor-in-Chief of Leukemia. He received the iCMLf Goldman Prize in 2022 and the CML Advocates Network Patient Advocacy Award in 2025.